Secukinumab: A Breakthrough in the Treatment of Autoimmune Disease

Author(s)	V.P.Kuzhali
Country	India
Abstract	Secukinumab is a significant advancement in the treatment of autoimmune disease, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. By targeting interleukin-17A(IL-17A), it offers a focused approach to mitigating inflammation. This article provides a comprehensive overview of Secukinumab, exploring its mechanism of action, clinical efficacy, safety profile, administration, and ongoing research aimed at expanding its therapeutic scope.
Keywords	Secukinumab, autoimmune disease, IL-17A, psoriasis, psoriatic arthritis, ankylosing spondylitis, biologic therapy
Field	Medical / Pharmacy
Published In	Volume 6, Issue 3, May-June 2024
Published On	2024-05-11
Cite This	Secukinumab: A Breakthrough in the Treatment of Autoimmune Disease - V.P.Kuzhali - IJFMR Volume 6, Issue 3, May-June 2024. DOI 10.36948/ijfmr.2024.v06i03.20102
DOI	https://doi.org/10.36948/ijfmr.2024.v06i03.20102
Short DOI	https://doi.org/gttvc6

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research